Holen Sie sich die Stockscreener-App
2.841
5.90%
-0.189
Schlusskurs vom Vortag:
$3.03
Offen:
$3.06
24-Stunden-Volumen:
1.02M
Relative Volume:
0.45
Marktkapitalisierung:
$432.33M
Einnahmen:
$38.69M
Nettoeinkommen (Verlust:
$-108.95M
KGV:
-2.3239
EPS:
-1.2225
Netto-Cashflow:
$-141.09M
1W Leistung:
-7.43%
1M Leistung:
-1.00%
6M Leistung:
+22.90%
1J Leistung:
+3.31%
1-Tages-Spanne:
$2.81
$3.06
1-Wochen-Bereich:
$2.84
$3.23
52-Wochen-Spanne:
$1.66
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.815 | 465.35M | 38.69M | -108.95M | -141.09M | -1.2225 |
VRTX
Vertex Pharmaceuticals Inc
|
522.72 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.64 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com India
New medical chief can earn the right to buy 950,000 Editas shares - Stock Titan
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - GlobeNewswire
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - MarketBeat
Editas Medicine, Inc. SEC Filing (Sep 9, 2026) - Stock Titan
EDIT: EDIT-401 aims for unprecedented LDL reduction, with first human data expected in 2027 - TradingView
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR By Investing.com - Investing.com India
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com
Editas Medicine Appoints Dan Ory as Chief Medical Officer - citybiz.co
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com Canada
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - Yahoo Finance
Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - kalkinemedia.com
Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - kalkinemedia.com
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat
Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - kalkinemedia.com
Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan
Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - Stock Titan
Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn
EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Boston and New York will host Editas Medicine talks this month - Stock Titan
Editas Medicine Files $400 Million Mixed Shelf - marketscreener.com
O'Neill plans another Editas (NASDAQ: EDIT) sale after June share trade - Stock Titan
Editas Medicine (EDIT) officer flags 700-share stock sale - Stock Titan
Editas Medicine stock holds steady as investors weigh latest gene editing progress - AD HOC NEWS
Nantahala Capital Management LLC Acquires Shares of 852,700 Editas Medicine, Inc. $EDIT - MarketBeat
EDIT Price History for Editas Medicine Stock - Barchart.com
Editas Medicine Inc. (EDIT) Peer Comparison – Compare with Others - Value Research
ADAR1 Capital Management LLC Buys New Stake in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Certain Stock Options of Editas Medicine, Inc. are subject to a Lock-Up Agreement Ending on 25-AUG-2026. - marketscreener.com
EDIT Stock Price, Quote & Chart - ChartMill
ETFs Investing in Editas Medicine, Inc. Stocks - TradingView
Editas Medicine (NASDAQ:EDIT) Trading 14.4% HigherHere's What Happened - MarketBeat
Ladenburg Thalmann Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $6 - Moomoo
EDIT Initiates Coverage On Ladenburg ThalmannRating Set to Bu - GuruFocus
Editas Medicine (NASDAQ:EDIT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
367,147 Shares in Editas Medicine, Inc. $EDIT Bought by GSA Capital Partners LLP - MarketBeat
EDIT Q2 2026 Earnings: Narrower-than-Expected Loss Underscores Cost DisciplineRevenue Growth Report - vinanet.vn
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Editas Medicine Inc (EDIT) Stock Price, Trades & News - GuruFocus
Editas Medicine (EDIT): ADAR1 Capital and Schneeberger disclose 5.8% ownership - Stock Titan
Editas Medicine (EDIT) Slides 3.7% as Gene-Editing Stock Tests Key Support at $2.70Collar Trade - vinanet.vn
Editas Medicine (EDIT) Institutional Ownership 2026 $EDIT - MarketBeat
Editas Medicine, Inc. (EDIT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Editas Medicine (EDIT) Short Interest & Short Float | Updated Aug 2026 $EDIT - MarketBeat
Editas Medicine (EDIT) Slips to $2.81 as Gene-Editing Stock Nears Critical SupportSchiff Line - dars.gov.et
Editas Medicine, Inc. (EDIT) stock price, news, quote and history - Yahoo Finance Singapore
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):